Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;61(5):922-4.
doi: 10.1002/pbc.24800. Epub 2013 Oct 26.

Initial Testing (Stage 1) of the Topoisomerase II Inhibitor Pixantrone, by the Pediatric Preclinical Testing Program

Affiliations
Free PMC article

Initial Testing (Stage 1) of the Topoisomerase II Inhibitor Pixantrone, by the Pediatric Preclinical Testing Program

Raushan T Kurmasheva et al. Pediatr Blood Cancer. .
Free PMC article

Abstract

Pixantrone, a novel aza-anthracenedione with cytotoxic activity, was tested against the PPTP in vitro panel (3.0 nM to 30.0 μM) and against a limited panel of PPTP Wilms tumors and sarcomas (7.5 mg/kg) administered intravenously using an every 4 day × 3 schedule. In vitro pixantrone showed a median relative IC50 value of 54 nM (range <3 nM to 1.03 μM). In vivo pixantrone induced significant differences in EFS distribution compared to controls in two of eight solid tumor xenografts at dose levels relevant to human drug exposure. A complete response was observed for one Wilms tumor xenograft.

Keywords: developmental therapeutics; preclinical testing; topoisomerase 2 inhibitor.

Conflict of interest statement

Conflict of interest statement: Cecilia Allievi is an independent consultant contracted with Cell Therapeutics, the other authors consider that there are no actual or perceived conflicts of interest.

Similar articles

See all similar articles

Publication types

MeSH terms

Feedback